Nonpigmented Serratia marcescens caused a formidable epidemic at the Nashville Veterans Administration (VA) Hospital during 1974. Multiply drug-resistant strains resulted in over 130 infections and 12 documented bacteremias and were associated with seven deaths. The majority of isolates were resistant to all commerically available antimicrobial agents for therapy of systemic infections including gentamicin. Over half the strains were susceptible to naladixic acid. Occasional susceptibility to chloramphenicol and kanamycin was observed, especially late in the epidemic. All strains were susceptible to amikacin (BB-K8) and resistant to tobramycin.
The combination of infectivity, pathogenicity, and multiple drug resistance prompted us to investigate several modes of therapy against resistant S. marcescens. Amikacin has proved efficacious for therapy of resistant Serratia infections (Prog. Abstr. Intersci. Conf. Antimicrob. Agents Chemother., 14th, San Fran- cisco, Calif., Abstr. 327, 1974 ). However, due to its investigational status, its usage was not practical in all patients. Furthermore, investigation of other modes of antimicrobial therapy was pursued due to concern over potential acquisition of resistance if amikacin were the only therapeutic agent used in a large epidemic. Having first confirmed in vitro reports of the efficacy of sulfamethoxazole -trimethoprimpolymixin (STP) against Serratia (7, 14) in our laboratory, we proceeded to use this combination in the treatment of six acutely ill patients infected with multiply drug-resistant S. marcescens.
MATERIALS AND METHODS
Strains were isolated in the Microbiology Laboratory of the Nashville VA Hospital, and identification was confirmed and serotyping was Bacteria. Static synergism was demonstrated with three antibiotic combinations -STP, rifampin-polymyxin, and chloramphenicol-polymyxin. Isobolograms constructed from checkerboard assays indicating significant synergism are depicted in Fig. 2 . STP bactericidal effects against Serratia were striking. Killing curves by STP of multiply drug-resistant Serratia strains from blood culture isolates are depicted in Fig. 3 (Fig. 4) Synergistic effects of STP in vitro against a number of gram-negative bacilli including S. marcescens have been previously recorded (7, 14, 15, 18, 19 ), yet few clinical trials have been forthcoming. In vitro static and cidal tests in our laboratory confirmed the synergistic effect of this three-drug combination against multiply drug-resistant S. marcescens obtained from clinical isolates. The rifampin-polymyxin combination, which also revealed in vitro cidal synergism but was not tried clinically, could provide another useful drug regimen when multiply drug-resistant Serratia outbreaks occur.
Clinically, the STP combination was well tolerated in most instances. Possible renal toxicity occurred in two patients, although continuing infection and obstructive uropathy probably produced azotemia in one. In the other terminally ill patient, azotemia without other demonstrable etiology accompanied by an increase in serum creatinine from 1 to 2.7 occurred during STP therapy. Colistimethate potential for nephrotoxicity is well described (11) , and trimethoprim-sulfamethoxazole nephrotoxicity, though apparently less frequent, may also be a hazard (9) . Accordingly, the combination STP should be used cautiously, with routine every-other-day determinations of blood urea nitrogen and serum creatinine. Components of the STP combination should be reduced appropriately (12, 21) in the face of preexisting renal failure with discontinuation of the combination should further renal decompensation occur. Reasoning from isobolograms indicating significant synergism with as little as 1.56 ,ug of colistimethate per ml (Fig. 3) , low-dosage colistimethate (2.5 mg/kg per day) should provide effective synergism with minimal nephrotoxic effects in patients with normal renal function. Further reduction in colistimethate dosage could be entertained when high serum cidal levels are demonstrated.
Therapy with STP was apparently efficacious in four of six patients. Two of four improving patients were bacteriological cures. The third benefited patient's urine was sterilized during two genitourinary operations, but relapse ofthe ANrIMICROB. AGENTS CHEMOTHER. urinary tract infection subsequently occurred. The fourth patient was relieved of fever and sepsis, though urinary Serratia carriage persisted due to the presence of an indwelling catheter.
Two patients (3 and 4, Table 1) were considered therapeutic failures. However, patient 3 died after only 4 days of therapy and patient 4 had tumor-induced obstructive uropathy, which would be expected to overwhelmingly compromise the efficacy of any drug or combination of antimicrobial agents. We view improvement of these very ill patients on STP therapy as probably significant in light of their underlying disease.
In vitro confirmation of adequacy of serum levels of a three-drug antimicrobial combination for therapy of serious infections is mandatory. Assay of each of the three drugs individually is impractical in most hospitals. Biological assays for antibiotics utilizing growth inhibition of organisms of known susceptibilities, which are used in the majority of special infectious diseases laboratories, cannot discriminate between three antibiotics. Efficacy of multi-drug therapeutic regimens for bacterial endocarditis may be guided by the serum bactericidal test introduced by Schlicter et al. (2, 17). Though not directly relevant to the management of our patients' infections, especially of the urinary tract, the serum bactericidal test appears to provide a practical guide to efficacy of therapy with STP. STP levels of 1:8 or greater were obtained in five of six patients, indicating effective systemic anti-Serratia therapy.
Despite the small number of patients treated, we conclude that our results are encouraging enough for further trials of STP 
